Short Interest in Covalon Technologies Ltd. (OTCMKTS:CVALF) Drops By 92.3%

Covalon Technologies Ltd. (OTCMKTS:CVALF) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 100 shares, a drop of 92.3% from the December 31st total of 1,300 shares. Based on an average trading volume of 20,700 shares, the short-interest ratio is presently 0.0 days.

Covalon Technologies Stock Performance

CVALF traded down $0.01 during midday trading on Tuesday, reaching $2.13. 7,847 shares of the company were exchanged, compared to its average volume of 31,644. Covalon Technologies has a one year low of $0.74 and a one year high of $3.08. The company’s fifty day moving average price is $2.40 and its 200 day moving average price is $2.25. The company has a market cap of $58.36 million, a price-to-earnings ratio of 30.43 and a beta of -0.27.

Covalon Technologies (OTCMKTS:CVALF) last posted its earnings results on Tuesday, January 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Covalon Technologies had a net margin of 8.58% and a return on equity of 12.33%.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.